Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and HMA Maintenance Post-Transplant for High-Risk Myeloid Malignancies
NCT05841771Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Shanghai General Hospital. Primary endpoint: Leukemia-free survival at 1 year. Started Jan 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05841771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841771.